Differences in the integrase and reverse transcriptase transmitted resistance patterns in Northern Poland

Infection, Genetics and Evolution

Volumn 49, Issue , 2017, Pages 122-129

  Parczewski, Miłosz ^a   Leszczyszyn Pynka, Magdalena ^a   Urbańska, Anna ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Integrase mutations; Non B subtypes; Transmission clusters; Transmitted drug resistance

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; GLUTAMIC ACID; GLUTAMINE; HEPATITIS C ANTIBODY; INTEGRASE; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AMINO ACID SUBSTITUTION; ANTIRETROVIRAL THERAPY; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLAND; SEQUENCE ANALYSIS; SEX DIFFERENCE; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; BAYES THEOREM; CLASSIFICATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MARKOV CHAIN; METABOLISM; MIDDLE AGED; MONTE CARLO METHOD; MUTATION RATE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; BAYES THEOREM; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV INTEGRASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; MUTATION RATE; PHYLOGENY; POLAND; SEX FACTORS;

EID: 85009495387     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2016.12.019     Document Type: Article

References (49)

1. Anstett, K., Mesplede, T., Oliveira, M., Cutillas, V., Wainberg, M.A., Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J. Virol. 89 (2015), 4681–4684.
2. Anstett, K., Cutillas, V., Fusco, R., Mesplede, T., Wainberg, M.A., Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. J. Antimicrob. Chemother. 71 (2016), 2083–2088.
3. Bennett, D.E., Camacho, R.J., Otelea, D., Kuritzkes, D.R., Fleury, H., Kiuchi, M., Heneine, W., Kantor, R., Jordan, M.R., Schapiro, J.M., Vandamme, A.M., Sandstrom, P., Boucher, C.A., van de Vijver, D., Rhee, S.Y., Liu, T.F., Pillay, D., Shafer, R.W., Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One, 4, 2009, e4724.
4. Boyd, S.D., Maldarelli, F., Sereti, I., Ouedraogo, G.L., Rehm, C.A., Boltz, V., Shoemaker, D., Pau, A.K., Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir. Ther. 16 (2011), 257–261.
5. Brenner, B.G., Wainberg, M.A., Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res., 12, 2016 (30283–30280).
6. Calvez, V., Marcelin, A.G., Vingerhoets, J., Hill, A., Hadacek, B., Moecklinghoff, C., Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons. Antivir. Ther. 21 (2016), 405–412.
7. Canducci, F., Marinozzi, M.C., Sampaolo, M., Boeri, E., Spagnuolo, V., Gianotti, N., Castagna, A., Paolucci, S., Baldanti, F., Lazzarin, A., Clementi, M., Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J. Antimicrob. Chemother. 65 (2010), 425–433.
8. Casadella, M., van Ham, P.M., Noguera-Julian, M., van Kessel, A., Pou, C., Hofstra, L.M., Santos, J.R., Garcia, F., Struck, D., Alexiev, I., Bakken Kran, A.M., Hoepelman, A.I., Kostrikis, L.G., Somogyi, S., Liitsola, K., Linka, M., Nielsen, C., Otelea, D., Paraskevis, D., Poljak, M., Puchhammer-Stockl, E., Stanekova, D., Stanojevic, M., Van Laethem, K., Zidovec Lepej, S., Clotet, B., Boucher, C.A., Paredes, R., Wensing, A.M., Primary resistance to integrase strand-transfer inhibitors in Europe. J. Antimicrob. Chemother. 70 (2015), 2885–2888.
9. Cavalcanti Jde, S., Ferreira, J.L., Guimaraes, P.M., Vidal, J.E., Brigido, L.F., High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen. J. Antimicrob. Chemother. 70 (2015), 926–929.
10. Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T.J., Higgins, D.G., Thompson, J.D., Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31 (2003), 3497–3500.
11. Danion, F., Belissa, E., Peytavin, G., Thierry, E., Lanternier, F., Scemla, A., Lortholary, O., Delelis, O., Avettand-Fenoel, V., Duvivier, C., Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region. J. Antimicrob. Chemother. 70:6 (2015), 1921–1923, 10.1093/jac/dkv012 (Epub 2015 Feb 10).
12. Doyle, T., Dunn, D.T., Ceccherini-Silberstein, F., De Mendoza, C., Garcia, F., Smit, E., Fearnhill, E., Marcelin, A.G., Martinez-Picado, J., Kaiser, R., Geretti, A.M., Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J. Antimicrob. Chemother. 70 (2015), 3080–3086.
13. Drummond, A.J., Suchard, M.A., Xie, D., Rambaut, A., Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol. Biol. Evol. 29 (2012), 1969–1973.
14. European AIDS Clinical Society, Guidelines v 8.1. http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf, 2016.
15. Goethals, O., Van Ginderen, M., Vos, A., Cummings, M.D., Van Der Borght, K., Van Wesenbeeck, L., Feyaerts, M., Verheyen, A., Smits, V., Van Loock, M., Hertogs, K., Schols, D., Clayton, R.F., Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antivir. Res. 91 (2011), 167–176.
16. Gutierrez, C., Hernandez-Novoa, B., Perez-Elias, M.J., Moreno, A.M., Holguin, A., Dronda, F., Casado, J.L., Moreno, S., Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants. HIV Clin. Trials 14 (2013), 10–16.
17. Han, Y.S., Mesplede, T., Wainberg, M.A., Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infect. Genet. Evol. 25 (2016), 30271–30274.
18. Harrigan PR, D.W., Wynhoven, B., Mo, T., Hall, T., Galli, R., The performance of ReCall basecalling software for high-throughput HIV drug resistance basecalling using “in-house” methods. XIV International AIDS Conference, Spain, Barcelona, 2002 (Abstract #TuPeB4598).
19. Hatano, H., Lampiris, H., Fransen, S., Gupta, S., Huang, W., Hoh, R., Martin, J.N., Lalezari, J., Bangsberg, D., Petropoulos, C., Deeks, S.G., Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 54 (2010), 389–393.
20. Hofstra, L.M., Sauvageot, N., Albert, J., Alexiev, I., Garcia, F., Struck, D., Van de Vijver, D.A., Asjo, B., Beshkov, D., Coughlan, S., Descamps, D., Griskevicius, A., Hamouda, O., Horban, A., Van Kasteren, M., Kolupajeva, T., Kostrikis, L.G., Liitsola, K., Linka, M., Mor, O., Nielsen, C., Otelea, D., Paraskevis, D., Paredes, R., Poljak, M., Puchhammer-Stockl, E., Sonnerborg, A., Stanekova, D., Stanojevic, M., Van Laethem, K., Zazzi, M., Zidovec Lepej, S., Boucher, C.A., Schmit, J.C., Wensing, A.M., Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin. Infect. Dis. 62 (2016), 655–663.
21. Hurt, C.B., Sebastian, J., Hicks, C.B., Eron, J.J., Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012. Clin. Infect. Dis. 58 (2014), 423–431.
22. Kobayashi, M., Nakahara, K., Seki, T., Miki, S., Kawauchi, S., Suyama, A., Wakasa-Morimoto, C., Kodama, M., Endoh, T., Oosugi, E., Matsushita, Y., Murai, H., Fujishita, T., Yoshinaga, T., Garvey, E., Foster, S., Underwood, M., Johns, B., Sato, A., Fujiwara, T., Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antivir. Res. 80 (2008), 213–222.
23. Lai, C.C., Liu, W.C., Fang, C.T., Yang, J.Y., Chang, L.H., Wu, P.Y., Luo, Y.Z., Chang, S.F., Su, Y.C., Chang, S.Y., Hung, C.C., Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan. J. Antimicrob. Chemother. 71 (2016), 226–234.
24. Mulu, A., Maier, M., Liebert, U.G., Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates. J. Transl. Med. 13 (2015), 015–0734.
25. Neogi, U., Haggblom, A., Santacatterina, M., Bratt, G., Gisslen, M., Albert, J., Sonnerborg, A., Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades. PLoS One, 9, 2014, e99390.
26. Palella, F.J. Jr., Armon, C., Buchacz, K., Chmiel, J.S., Novak, R.M., D'Aquila, R.T., Brooks, J.T., Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV outpatient study (HOPS). J. Antimicrob. Chemother. 69 (2014), 2826–2834.
27. Paraskevis, D., Pybus, O., Magiorkinis, G., Hatzakis, A., Wensing, A.M., van de Vijver, D.A., Albert, J., Angarano, G., Asjo, B., Balotta, C., Boeri, E., Camacho, R., Chaix, M.L., Coughlan, S., Costagliola, D., De Luca, A., de Mendoza, C., Derdelinckx, I., Grossman, Z., Hamouda, O., Hoepelman, I., Horban, A., Korn, K., Kucherer, C., Leitner, T., Loveday, C., Macrae, E., Maljkovic-Berry, I., Meyer, L., Nielsen, C., Op de Coul, E.L., Ormaasen, V., Perrin, L., Puchhammer-Stockl, E., Ruiz, L., Salminen, M.O., Schmit, J.C., Schuurman, R., Soriano, V., Stanczak, J., Stanojevic, M., Struck, D., Van Laethem, K., Violin, M., Yerly, S., Zazzi, M., Boucher, C.A., Vandamme, A.M., Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology, 6, 2009, 49.
28. Parczewski, M., Leszczyszyn-Pynka, M., Bander, D., Urbanska, A., Stanczak, G., Boron-Kaczmarska, A., Characteristics of HIV-1 non-B subtype infections in Northwest Poland. J. Med. Virol. 82 (2010), 1306–1313.
29. Parczewski, M., Bander, D., Urbanska, A., Boron-Kaczmarska, A., HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland. BMC Infect. Dis., 12, 2012, 368.
30. Parczewski, M., Leszczyszyn-Pynka, M., Bander, D., Urbanska, A., Boron-Kaczmarska, A., HIV-1 subtype D infections among caucasians from Northwestern Poland-phylogenetic and clinical analysis. PLoS One, 7, 2012, e31674.
31. Parczewski, M., Urbanska, A., Maciejewska, K., Witak-Jedra, M., Leszczyszyn-Pynka, M., Transmitted drug resistance to rilpivirine among antiretroviral-naive patients living with HIV from northern Poland. J. Int. AIDS Soc., 17, 2014, 18929.
32. Parczewski, M., Leszczyszyn-Pynka, M., Witak-Jedra, M., Maciejewska, K., Rymer, W., Szymczak, A., Szetela, B., Gasiorowski, J., Bociaga-Jasik, M., Skwara, P., Garlicki, A., Grzeszczuk, A., Rogalska, M., Jankowska, M., Lemanska, M., Hlebowicz, M., Baralkiewicz, G., Mozer-Lisewska, I., Mazurek, R., Lojewski, W., Grabczewska, E., Olczak, A., Jablonowska, E., Clark, J., Urbanska, A., Transmitted HIV drug resistance in antiretroviral-treatment-naive patients from Poland differs by transmission category and subtype. J. Antimicrob. Chemother. 70 (2015), 233–242.
33. Polish Scientific AIDS Society, Principles of Care for the HIV-infected Patients 2016 (in Polish) [Zasady opieki nad osobami zakażonymi HIV 2016]. 2016, PTN AIDS, Warszawa. Eko-Press.
34. Ragonnet-Cronin, M., Hodcroft, E., Hue, S., Fearnhill, E., Delpech, V., Brown, A.J., Lycett, S., Automated analysis of phylogenetic clusters. BMC Bioinf., 14, 2013, 317.
35. Ragonnet-Cronin, M., Lycett, S.J., Hodcroft, E.B., Hue, S., Fearnhill, E., Brown, A.E., Delpech, V., Dunn, D., Leigh Brown, A.J., Transmission of non-B HIV subtypes in the United Kingdom is increasingly driven by large non-heterosexual transmission clusters. J. Infect. Dis. 213 (2016), 1410–1418.
36. Rosinska, M., Marzec-Bogustawska, A., Janiec, J., Smolen-Dzirba, J., Wasik, T., Gniewosz, J., Zalewska, M., Murphy, G., McKinney, E., Porter, K., High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland. AIDS Res. Hum. Retrovir. 29 (2013), 805–813.
37. Rosinska, M., Gwiazda, P., D.E.A., D., Presanis, A.M., Bayesian evidence synthesis to estimate HIV prevalence in men who have sex with men in Poland at the end of 2009. Epidemiol. Infect., 2015, 1–17.
38. Sayan, M., Gunduz, A., Ersoz, G., Inan, A., Deveci, A., Ozgur, G., Sargin, F., Karagoz, G., Inci, A., Inan, D., Ulcay, A., Karaoglan, I., Kaya, S., Kutlu, S.S., Suer, K., Cagatay, A., Akalin, H., Integrase strand transfer inhibitors (INSTIs) resistance mutations in HIV-1 infected Turkish patients. HIV Clin. Trials 17 (2016), 109–113.
39. Scherrer, A.U., Yang, W.L., Kouyos, R.D., Boni, J., Yerly, S., Klimkait, T., Aubert, V., Cavassini, M., Battegay, M., Hauser, C., Calmy, A., Schmid, P., Bernasconi, E., Gunthard, H.F., Successful prevention of transmission of integrase resistance in the Swiss HIV cohort study. J. Infect. Dis. 214 (2016), 399–402.
40. Smolen-Dzirba, J., Rosinska, M., Kruszynski, P., Bratosiewicz-Wasik, J., Janiec, J., Beniowski, M., Bociaga-Jasik, M., Jablonowska, E., Szetela, B., Porter, K., Wasik, T.J., Molecular epidemiology of recent HIV-1 infections in southern Poland. J. Med. Virol. 84 (2012), 1857–1868.
41. Stekler, J.D., McKernan, J., Milne, R., Tapia, K.A., Mykhalchenko, K., Holte, S., Maenza, J., Stevens, C.E., Buskin, S.E., Mullins, J.I., Frenkel, L.M., Collier, A.C., Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007–2013. Antivir. Ther. 20 (2015), 77–80.
42. Tostevin, A., White, E., Dunn, D., Croxford, S., Delpech, V., Williams, I., Asboe, D., Pozniak, A., Churchill, D., Geretti, A.M., Pillay, D., Sabin, C., Leigh-Brown, A., Smit, E., Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med., 1, 2016, 12414.
43. Tsiang, M., Jones, G.S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R.A., Stepan, G., Stray, K.M., Niedziela-Majka, A., Yant, S.R., Yu, H., Kukolj, G., Cihlar, T., Lazerwith, S., White, K.L., Jin, H., Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob. Agents Chemother., 2016.
44. Van Laethem, K., Schrooten, Y., Covens, K., Dekeersmaeker, N., De Munter, P., Van Wijngaerden, E., Van Ranst, M., Vandamme, A.M., A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J. Virol. Methods 153 (2008), 176–181.
45. Wensing, A.M., Calvez, V., Gunthard, H.F., Johnson, V.A., Paredes, R., Pillay, D., Shafer, R.W., Richman, D.D., 2015 Update of the drug resistance mutations in HIV-1. Top Antivir. Med. 23 (2015), 132–141.
46. Williams, I., Churchill, D., Anderson, J., Boffito, M., Bower, M., Cairns, G., Cwynarski, K., Edwards, S., Fidler, S., Fisher, M., Freedman, A., Geretti, A.M., Gilleece, Y., Horne, R., Johnson, M., Khoo, S., Leen, C., Marshall, N., Nelson, M., Orkin, C., Paton, N., Phillips, A., Post, F., Pozniak, A., Sabin, C., Trevelion, R., Ustianowski, A., Walsh, J., Waters, L., Wilkins, E., Winston, A., Youle, M., British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 13:Suppl. 2 (2012), 1–85.
47. Wohl, D.A., Cohen, C., Gallant, J.E., Mills, A., Sax, P.E., Dejesus, E., Zolopa, A., Liu, H.C., Plummer, A., White, K.L., Cheng, A.K., Rhee, M.S., Szwarcberg, J., A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J. Acquir. Immune Defic. Syndr. 65 (2014), e118–e120.
48. Yebra, G., Delgado, R., Pulido, F., Rubio, R., Galan, J.C., Moreno, S., Holguin, A., Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade. Arch. Virol. 159 (2014), 1079–1087.
49. Yoshinaga, T., Kobayashi, M., Seki, T., Miki, S., Wakasa-Morimoto, C., Suyama-Kagitani, A., Kawauchi-Miki, S., Taishi, T., Kawasuji, T., Johns, B.A., Underwood, M.R., Garvey, E.P., Sato, A., Fujiwara, T., Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob. Agents Chemother. 59 (2015), 397–406.